We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


MorphoSys to Receive Milestone Payment for Guselkumab Program

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "MorphoSys to Receive Milestone Payment for Guselkumab Program"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time:

MorphoSys AG has announced that its collaborator Janssen Biotech, Inc. (Janssen) has initiated a phase 2 clinical trial in psoriatic arthritis with the HuCAL antibody guselkumab (CNTO1959). The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.

"We are delighted to see Janssen moving guselkumab into a new clinical program for psoriatic arthritis," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news marks the first of up to six clinical milestone events we expect to see with partners this year."

MorphoSys's collaboration with Janssen has resulted in three clinical programs to date, two of which are in phase 2 development and one, guselkumab, in phase 3 in psoriasis (most advanced trial).

In total, MorphoSys's partnered and proprietary clinical pipeline currently comprises 23 unique antibody molecules which are being evaluated in more than 60 clinical trials.